Use of Direct-acting Antiviral Therapy to Prevent Spread of HCV Infection for Patients Receiving a HCV Positive Kidney Transplant as a HCV Negative Recipient

Trial Profile

Use of Direct-acting Antiviral Therapy to Prevent Spread of HCV Infection for Patients Receiving a HCV Positive Kidney Transplant as a HCV Negative Recipient

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 31 Jan 2020 to 31 Jan 2021.
    • 04 Oct 2017 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
    • 04 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top